We are dedicated to translating scientific breakthroughs into effective treatments for people with Alzheimer’s disease through cutting-edge research and comprehensive clinical trials.

Explore a selection of our accomplished works, including:

2024

pdf
2024 CTAD Presentation: ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in …
pdf
2024 AAIC Poster: INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews …
pdf
2024 AAIC Poster: Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 …
pdf
2024 AAIC Poster: INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug …
pdf
2024 AAIC Poster:  INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants …
pdf
2024 ADPD Presentation: Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in …
pdf
2024 ADPD Poster:   Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug …
pdf
2024 AAN Presentation:   A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and …
pdf
2024 AAN Poster:   A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and …
9 documents

2023

pdf
2023 CTAD Poster: Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase …
pdf
2023 ADPD Poster:   Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived Excitatory …
pdf
2023 AAIC Presentation:   Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting …
pdf
2023 CTAD Presentation:   INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, …
pdf
2023 CTAD Poster:   INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
pdf
2023 CTAD Poster:   Incorporating the Study Participant’s Voice into Early Development of ACU193 for …
pdf
2023 CTAD Poster:   ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay …
7 documents

2022

93
2022 Journal of Prevention of Alzheimer’s Disease:   ACU193, a Monoclonal Antibody that Selectively Binds …
848215
2022 Frontiers in Neuroscience:   ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer …
pdf
2022 AAIC Poster:   Preparation and qualification of soluble AβOs for use in bioanalytical assays …
pdf
2022 CTAD Poster:   Critical evaluation and comparison of biomarker values in commercial CSF with …
4 documents

2021

pdf
2021 CTAD Presentation:   Phase 1 trial design for ACU193, a monoclonal antibody that selectively …
1 document

2019

pdf
2019 AAIC Poster:   Soluble Aβ-Oligomer–Selective Antibody ACU3B3 Reduces Amyloid Pathology & Improves Multiple Behavioral …
pdf
2019 CTAD Poster Synaptic intervention in Alzheimer’s disease: soluble Aβ oligomer directed ACU193 monoclonal antibody …
2 documents

2017

pdf
2017 SfN Poster:   Oligomeric Ab-induced neuronal toxicity is attenuated by ADDL-specific antibodies in vivo.
1 document

2014

pdf
2014 SfN Poster Soluble Aβ-oligomer-selective Antibody ACU-3B3 Reduces Amyloid Pathology and Improves Multiple Behavioral Domains …
pdf
2014 SfN Poster:   Passive immunization with the anti-Aβ oligomer antibody ACU-3B3 improves behavioral deficits …
2 documents